| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA796: Venetoclax for treating chronic lymphocytic leukaemia |
|
Medicine details |
|
| Medicine name | venetoclax (Venclyxto®) |
| Formulation | 10 mg, 50 mg, 100 mg film-coated tablet |
| Reference number | 2484 |
| Indication | Monotherapy for the treatment of chronic lymphocytic leukaemia in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor; monotherapy for the treatment of chronic lymphocytic leukaemia in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor |
| Company | AbbVie Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 24/11/2016 |
| NICE guidance | TA796: Venetoclax for treating chronic lymphocytic leukaemia |
| Commercial arrangement | PAS |